Garry E. Menzel's Insider Trades & SAST Disclosures
Garry E. Menzel's most recent trade in Adaptimmune Therapeutics Plc - ADR was a trade of 1,121,604 Option to purchase Ordinary Shares done . Disclosure was reported to the exchange on July 1, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Garry E. Menzel.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics P... | Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,121,604 | 1,121,604 | - | - | Option to purchase Ordinary Shares | |
| Black Diamond Therapeutics... | Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 30,550 | 30,550 | - | - | Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2023 | 16,500 | 16,500 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges